No Data
No Data
Intra-Cellular Therapies, Standard BioTools, SI-BONE And Other Big Stocks Moving Higher On Monday
Express News | Blueprint Medicines Shares Are Trading Higher After the Company Reported a Year-over-year Increase in FY24 AYVAKIT Revenue Results
Wedbush Reiterates Outperform on Blueprint Medicines, Lowers Price Target to $124
A Quick Look at Today's Ratings for Blueprint Medicines(BPMC.US), With a Forecast Between $105 to $151
Blueprint Medicines (BPMC) Gets a Buy From TD Cowen
Express News | Blueprint Medicines Corp : Wedbush Cuts Target Price to $124 From $135
No Data